Abstract
The clinical dosage formulation of Paclitaxel and Docetaxel, Taxol® and Taxotere®, while having high efficacy, can cause serious side effects due to the adjuvant used. We have developed a system of nanoparticles (NPs) of biodegradable copolymer, poly(lactic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS), for Docetaxel formulation to achieve enhanced, sustainable and controlled chemotherapeutic effectiveness and reduce the undesirable side actions. Docetaxel-loaded PLA-TPGS NPs were synthesized with desired size and physicochemical and pharmaceutical properties. In vitro studies using MCF-7 cancer cells have demonstrated the higher cellular uptake and therapeutic effects of the NP formulation. In vivo pharmacokinetics and biodistribution analysis have shown that one dose of the NP formulation of Docetaxel can achieve a 360-h effective chemotherapy with 3.44-fold higher therapeutic effect and 4.42-fold lower side effect than that of Taxotere® at the same dose of 10 mg/kg, as indicated by the larger area-under-the-curve and better biodistribution.
Keywords: Anticancer drugs, biodegradable polymers, cancer nanotechnology, chemotherapeutic engineering, nanomedicine
Current Pharmaceutical Design
Title: Nanomedicine: Enhancement of Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle Formulation
Volume: 16 Issue: 21
Author(s): Chee Wee Gan, Shu Chien and Si-Shen Feng
Affiliation:
Keywords: Anticancer drugs, biodegradable polymers, cancer nanotechnology, chemotherapeutic engineering, nanomedicine
Abstract: The clinical dosage formulation of Paclitaxel and Docetaxel, Taxol® and Taxotere®, while having high efficacy, can cause serious side effects due to the adjuvant used. We have developed a system of nanoparticles (NPs) of biodegradable copolymer, poly(lactic acid)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS), for Docetaxel formulation to achieve enhanced, sustainable and controlled chemotherapeutic effectiveness and reduce the undesirable side actions. Docetaxel-loaded PLA-TPGS NPs were synthesized with desired size and physicochemical and pharmaceutical properties. In vitro studies using MCF-7 cancer cells have demonstrated the higher cellular uptake and therapeutic effects of the NP formulation. In vivo pharmacokinetics and biodistribution analysis have shown that one dose of the NP formulation of Docetaxel can achieve a 360-h effective chemotherapy with 3.44-fold higher therapeutic effect and 4.42-fold lower side effect than that of Taxotere® at the same dose of 10 mg/kg, as indicated by the larger area-under-the-curve and better biodistribution.
Export Options
About this article
Cite this article as:
Wee Gan Chee, Chien Shu and Feng Si-Shen, Nanomedicine: Enhancement of Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle Formulation, Current Pharmaceutical Design 2010; 16 (21) . https://dx.doi.org/10.2174/138161210791920487
DOI https://dx.doi.org/10.2174/138161210791920487 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of NF-kB Activation and Cytokines Production in THP-1 Monocytes by 2-Styrylchromones
Medicinal Chemistry Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Development of New Potential Anticancer Metal Complexes Derived from 2-Hydrazinobenzothiazole
Mini-Reviews in Medicinal Chemistry Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer Cells
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Targeting Carcinogen Metabolism by Dietary Cancer Preventive Compounds
Current Cancer Drug Targets The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Clinical Trials in Children
Reviews on Recent Clinical Trials Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Design and Synthesis of Novel Thiosemicarbazones as Potent Anti-breast Cancer Agents
Letters in Drug Design & Discovery Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art
Current Drug Metabolism Meet Our Editorial Board Member:
Central Nervous System Agents in Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Letters in Drug Design & Discovery The p53-Estrogen Receptor Loop in Cancer
Current Molecular Medicine Editorial:
Pharmaceutical Nanotechnology Human Immunodeficiency Virus-Induced Apoptosis of Human Breast Cancer Cells Via CXCR4 is Mediated by the Viral Envelope Protein But Does Not Require CD4
Current HIV Research Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy